Advertised rate
From $93/month
Format
Nasal spray
Bottle volume
Not verified in the reviewed offer
Access
Online health intake and clinician review
Delivery
Free shipping advertised

A nasal product with its own decision

CoreAge Rx lists NAD+ Nasal Spray at the same $93 monthly starting price as its injection product. The shared number simplifies the catalog but does not imply that one bottle contains an equivalent course or produces equivalent effects. Nasal delivery involves a different formulation and device, and the decision to prescribe it should be evaluated separately.

For a reader who would prefer to avoid injections, convenience is a legitimate preference to discuss. It should sit alongside the intended reason for treatment, the limits of the evidence and the clinician's assessment, rather than replace those questions.

What is missing from a price-only comparison

The reviewed starting-price offer does not establish the bottle volume or the amount dispensed by its pump. Without those details, there is no defensible price-per-milliliter comparison with another nasal product. Even when both figures are known, a cost-per-volume calculation says nothing about equivalence between formulations.

Ask the provider to identify the concentration, bottle quantity, expected refill period and whether the quote includes every recurring charge. A monthly advertisement can describe a payment schedule while leaving the actual supply period dependent on the prescription. Those periods should be recorded separately.

Storage and practical use belong to the pharmacy

A nasal bottle introduces questions that do not appear in the same form for a vial: pump preparation, device care, transport and the usable period once opened. The pharmacy's product-specific information should govern these details. Advice for another company's spray, or for CoreAge Rx's injectable, should not be substituted.

Before a shipment arrives, know whom to contact if the pump is damaged or the delivery has an unexpected delay. Ask whether a replacement requires returning packaging, photographs or another form of documentation. Clear instructions reduce the temptation to improvise with an unfamiliar preparation.

Read brain-delivery language cautiously

The provider makes cognitive and brain-delivery claims for nasal NAD+. We do not present those statements as proof of improved memory, prevention of neurological disease or long-term safety. Experimental work on a route of administration and research on related molecules cannot automatically validate the exact commercial spray a patient receives.

A useful consultation distinguishes the patient's goal from the proposed mechanism. For example, a desire for better concentration should prompt discussion of possible contributing factors and realistic follow-up, not an assumption that the route guarantees delivery to a particular tissue or a predictable subjective effect.

The quote that makes comparison possible

CoreAge Rx advertises no membership fee, free delivery and no long-term contract. Reconcile those statements with the selected product's first charge, renewal timing and cancellation cutoff. A no-contract description does not explain whether an order already sent to the pharmacy can be stopped or refunded.

At an unchanged $93 for twelve months, the simple medication scenario would total $1,116. That is an illustration using the advertised floor, not a promised annual bill. The more useful comparison is the written plan for the actual bottle, plus an honest account of what the route's evidence can and cannot establish. Featured placement remains commercial.

Useful distinctions

  • Injection-free format is clearly identified
  • Starting monthly price is public
  • Shipping and membership statements are explicit

Limitations to weigh

  • Bottle volume and pump output require confirmation
  • No established equivalence with the injection offer
  • Cognitive marketing is not proof of clinical benefit

Sources & further reading

Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.

  1. CoreAge Rx NAD+ Nasal Provider
  2. FDA: Compounding questions and answers Regulator
  3. Grant et al. 2019: Human plasma and urine metabolome during NAD+ IV infusion Clinical research